Palo Alto Networks, Ambarella, Broadcom and More Major Earnings Coming This Week
24/7 Wall St. has put together a preview of Broadcom, Cloudera and some of the other top companies reporting their latest results in the coming week.
All Work
Chris Lange
Wedbush’s Red-Hot Best Idea List Going Into Summer
Wedbush's Best Ideas list has beat the S&P 500 year to date and includes Activision Blizzard, Facebook, Foot Locker and more.
Double Trouble for Harley-Davidson: Price & Demand
Harley-Davidson has had a rough go of 2018, with its stock down about 19% so far. While the overall market climate might be to blame for most of this drop, Harley still has to…
Friday’s Biggest Winners and Losers in the S&P 500
Friday was a solid day for the broad U.S. markets closing out what has been a tumultuous week. Crude oil backed off again, pushing even closer to $65. The S&P 500 sectors were almost…
ISM Manufacturing Cruises Even Higher
The most recent ISM manufacturing report points to stronger conditions for a sector that looks to be picking up steam.
Why Marvell Technology Earnings Are Good Enough
Marvell Technology shares rose after it released better-than-expected fiscal first-quarter financial results late Thursday.
May Employment Numbers Charge Forward
The U.S. Department of Labor released its Employment Situation numbers for the month of May early on Friday.
Cheers for Abercrombie & Fitch’s Q1 Are Short-Lived
Abercrombie & Fitch reported better-than-expected quarterly results before the markets opened on Friday, but shares tumbled afterward.
How Lululemon Blew Out Q1
Lululemon Athletica shares jumped after the company released better-than-expected fiscal first-quarter financial results.
Thursday’s Biggest Winners and Losers in the S&P 500
Thursday was a down day for the broad U.S. markets after what was an excellent recovery on Wednesday. Crude oil backed off again, counteracting most of the gains from Wednesday. The S&P 500 sectors…
Is Facebook Falling Out of Favor With Teens?
For the longest time Facebook has been the dominant force in social media, but now among America’s youth this platform is falling to the wayside. According to a new study from the Pew Research…
What to Expect When Costco Reports After the Close
Analysts expect top and bottom line growth when Costco releases its most recent quarterly results after the markets close on Thursday.
Why Positive Results Just Aren’t Good Enough for Clearside Bio
Clearside Biomedical shares were dropping early on Thursday after the company released data from its midstage clinical trial of Eylea for diabetic macular edema.
American Eagle’s Record Sales Fail to Impress
American Eagle Outfitters released its fiscal first-quarter financial results before the markets opened on Thursday.
GM Cruise Lands a Multibillion Investment From SoftBank
GM shares saw a solid gain on Thursday after it was announced that SoftBank Vision Fund would be making a sizable investment in the GM Cruise.
How Newsoara Bio Is Saving vTv Therapeutics
vTv Therapeutics watched its shares make a massive gain early on Thursday after the firm announced an exclusive licensing agreement with Newsoara Biopharma.
CRISPR Faces FDA Clinical Hold
CRISPR Therapeutics shares saw a significant drop on Thursday morning after an announcement that the FDA placed a clinical hold on the Investigational New Drug Application (IND) for CTX001 for the treatment of sickle…
Wednesday’s Biggest Winners and Losers in the S&P 500
Wednesday was a solid recovery for the broad U.S. markets after a slow start to this shortened trading week. Crude oil saw also saw a big recovery in Wednesday’s session. The S&P 500 sectors…
Risks Might Overshadow Sunny Outlook for World Economy
According to the OECD's latest economic outlook, the global economy is seeing stronger growth as the result of a recovery in trade, higher investment and increased job creation. However, this outlook does have some…
How Immutep Is Making Waves With Its Keytruda Combination
Immutep shares saw a nice gain in Wednesday’s session after the company released new data from its early-stage clinical trial in unresectable or metastatic melanoma patients.